검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gemcitabine + nab-paclitaxel (gemcitabine + nab-paclitaxel) Verastem, Inc.·Metastatic Pancreatic Carcinoma ORR 80% |
|---|---|
Overview Program | gemcitabine + nab-paclitaxel |
Overview Company | Verastem, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Pancreatic Carcinoma |
Overview Indication | Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | Biomarker Monitoring |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2).. Pancreatic ductal adenocarcinoma remains a malignancy with a dismal prognosis, characterized by a… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gemcitabine + nab-paclitaxel (gemcitabine + nab-paclitaxel) Verastem, Inc.·Metastatic Pancreatic Carcinoma ORR 80% |
|---|---|
Overview Program | gemcitabine + nab-paclitaxel |
Overview Company | Verastem, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Pancreatic Carcinoma |
Overview Indication | Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | Biomarker Monitoring |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2).. Pancreatic ductal adenocarcinoma remains a malignancy with a dismal prognosis, characterized by a… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical PFS | 10 |
Clinical OS | 33.6 |
Clinical Result source | ClinicalTrials.gov NCT02759588 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교